健康和医疗产品提供商Shineco战略性收购扩展全球区块链-生物科技网络-动脉网

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchainiotech Network

CISION 等信源发布 2025-08-20 18:30



可切换为仅中文







BEIJING

北京

，

Aug. 20, 2025

2025年8月20日

/PRNewswire/ -- Shineco Inc. ('Shineco' or the 'Company'; NASDAQ:

/PRNewswire/ -- 天之骄子公司（“天之骄子”或“公司”；纳斯达克：

SISI

西西

), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a 'Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement' with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based

），一家在诱导性多能干细胞（iPSC）技术领域的领先创新者，今天宣布与区块链基础设施提供商Plus Me Limited签署了“细胞资产上链与营销生态系统合作协议”。此次合作将实现基于区块链的

tokenization

分词

of biological cellular assets, facilitating seamless global transfers and auditable standardized custody, creating a novel 'Asset On-Chaining + Application Scenarios' model in cell therapy. The collaboration will redefine the global biological cell industry's commercial architecture.

生物细胞资产，促进无缝的全球转移和可审计的标准化保管，在细胞治疗中创建了一个新的“资产上链+应用场景”模型。此次合作将重新定义全球生物细胞产业的商业架构。

Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells (MSCs) on the

根据协议，Plus Me 将在 Shineco 的合规间充质干细胞 (MSCs) 上部署全生命周期的数字保管。

Ethereum

以太坊

mainnet. Smart contracts will immutably secure asset ownership rights, issuing unique non-

主网。智能合约将不可更改地确保资产所有权，并发行独特的非同质化代币

fungible

可替代的

digital identifiers (NFDIs) for each cellular asset to ensure traceability and compliance. Verifiable uniqueness and regulatory compliance are cryptographically enforced through on-chain hashing.

为每个细胞资产提供数字标识符（NFDIs），以确保可追溯性和合规性。通过链上哈希加密技术，可验证的唯一性和法规遵从性得到强制执行。

Plus Me will issue ERC-1400/ERC-20 compliant security tokens, branded as 'Cell Infusion Redemption Tokens.' These utility tokens can be redeemed at Shineco-affiliated Cell Therapy Centers, with Tokens are programmatically burned upon redemption, enforcing scarcity and aligning long-term value for stakeholders.

Plus Me 将发行符合 ERC-1400/ERC-20 标准的安全代币，品牌为“细胞注入赎回代币”。这些实用代币可在 Shineco 附属的细胞治疗中心兑换，代币在兑换时会被程序化销毁，以确保稀缺性并为利益相关者实现长期价值。

This RWA (Real-World Asset) .

这是RWA（现实世界资产）。

tokenization

分词

framework addresses critical industry pain points: high user costs, unverifiable product provenance, and illiquid asset pools – converting biological assets into tradable digital instruments.

框架解决了关键的行业痛点：高用户成本、无法验证的产品来源和流动性差的资产池——将生物资产转化为可交易的数字工具。

To bolster the initiative, Shineco has secured a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd., a specialist in cryogenic cell storage and clinical applications, provides the off-chain infrastructure critical to

为了促进这一倡议，尚高公司已经获得了西安东澳健康管理有限公司51%的控股权，该公司是低温细胞存储和临床应用方面的专家，提供了至关重要的链下基础设施。

token

令牌

redemption, as of

赎回，如

August 18, 2025

2025年8月18日

. This strategic buyout operationalizes the

。此次战略性收购使运营得以实现

tokenization

分词

initiative, providing off-chain infrastructure for

主动性，提供链下基础设施

token

令牌

redemption. Combined with previously acquired

赎回。结合之前获得的

Singapore

新加坡

firm Infiniclone, Shineco now controls a global storage & infusion network ensuring on-chain<>off-chain asset settlement.

公司Infiniclone，Shineco现在控制着一个全球存储和注入网络，确保链上<>链下资产结算。

The parties will co-build an open-cell industry ecosystem: Plus Me provides

双方将共建开放蜂窝产业生态：Plus Me提供

tokenization

分词

SaaS to third parties, while Shineco opens its physical custody network. Shineco maintains off-chain biological QA, with Plus Me ensuring on-chain regulatory compliance – creating cross-jurisdictional synergy with entities like

向第三方提供SaaS服务，而尚科则开放其实体保管网络。尚科负责链下生物质量保证，Plus Me确保链上合规性——与跨司法管辖区的实体如…产生协同效应。

Singapore's

新加坡的

ACTRIS. This tokenized ecosystem transforms Shineco from a sole service provider into a global infrastructure provider for the cell economy, positioning the ecosystem for rapid revenue scalability.

ACTRIS。这个代币化的生态系统将 Shineco 从单一的服务提供商转变为细胞经济的全球基础设施提供商，使该生态系统具备快速收入扩展的能力。

Shineco's asset

天士力的资产

tokenization

分词

protocol aligns with the industry's shift from clinical trials to commercial scalability. 'This marks the birth of a

协议与行业从临床试验向商业可扩展性的转变相一致。‘这标志着一个

decentralized

去中心化的

biotech economy—where every cell becomes a liquid, programmable asset, unlocking unprecedented value for medicine and investors alike,' said

生物技术经济——每个细胞都成为一种流动的、可编程的资产，为医学和投资者释放出前所未有的价值，

Jennifer Zhan

詹妮弗·占

, CEO of Shineco. '

“，光辉科技的首席执行官。'

Token

令牌

holders gain governance rights, including future DAO voting to enhance global ecosystem development in cell therapy—fundamentally transforming traditional marketing paradigms.'

持有者获得治理权，包括未来通过DAO投票来促进细胞治疗领域的全球生态系统发展——从根本上转变传统的营销模式。

About Plus Me Limited

关于Plus Me有限公司

Plus Me provides enterprise-grade blockchain middleware, offering end-to-end solutions for

Plus Me 提供企业级区块链中间件，提供端到端的解决方案

digital asset

数字资产

compliance, tokenomics architecture, and cross-border liquidity deployment. The firm architects Web3 economic models with global exchange partnerships.

合规性、代币经济架构以及跨境流动性部署。该公司通过全球交易所合作构建Web3经济模型。

About Xi'an Dong'ao Health Management Co., Ltd.

关于西安东奥健康管理有限公司

Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via 'Prevention-Intervention-Maintenance' protocols.

西安东奥健康提供符合GMP规范的生物存储和临床细胞应用，通过“预防-干预-维护”方案实现综合健康管理。

About Shineco, Inc.

关于北京天地生农业发展有限公司

Shineco, Inc. ('Shineco' or the 'Company') aims to 'focus on healthy living and improve the quality of life' by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products.

神州控股（“神州”或“公司”）旨在通过向社会提供安全、高效和高质量的健康和医疗产品及服务来“专注于健康生活，提高生活质量”。公司的核心业务涵盖诱导多能干细胞 (iPSC) 技术平台和细胞外囊泡衍生产品。

For more information about Shineco, please visit .

有关Shineco的更多信息，请访问。

www.biosisi.com/

。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as 'may,' 'will,' 'should,' 'could,' 'intend,' 'expect,' 'plan,' 'budget,' 'anticipate,' 'believe,' 'estimate,' 'forecast,' 'potential,' 'continue,' 'evaluate' or similar words.

本新闻稿包含1933年《证券法》第27A条（经修订）和1934年《证券交易法》第21E条（经修订）所指的“前瞻性陈述”。这些前瞻性陈述可以通过诸如“可能”、“将”、“应该”、“可能”、“意图”、“预期”、“计划”、“预算”、“预计”、“相信”、“估计”、“预测”、“潜在”、“继续”、“评估”或类似词语来识别。

Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions.

前瞻性陈述不应被依赖，因为它们既不是历史事实，也不能保证未来的表现。相反，它们仅基于我们当前对未来业务、未来计划和战略、预测、预期事件和趋势、经济状况以及其他未来条件的信念、期望和假设。

Examples of forward-looking statements include, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake.

前瞻性陈述的例子包括：我们在产品和服务方面的创新和市场地位、我们的竞争优势，以及我们预期5分钟心脏测试将成为该领域满足即时检测需求的领先产品之一。

Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products an.

请勿依赖任何前瞻性陈述。由于各种因素，实际结果可能与历史结果或前瞻性陈述中显示的结果存在重大差异，这些因素包括但不限于公司获取额外资本的能力、维持和发展其业务的能力、经营成果的波动性、维护和提升其品牌的能力、开发和推出新产品和服务的能力、在其计划销售产品的司法管辖区获得所有必要监管批准的能力、拟收购的公司、以及成功将技术和资产整合到其产品组合中的能力。

For media inquiries or partnership opportunities, contact:

媒体咨询或合作机会，请联系：

Shineco, Inc.

天地人和有限公司

secretary@shineco.tech

秘书@shineco.tech

Mobile: +86-010-68130220

手机：+86-010-68130220

SOURCE Shineco,Inc.

来源：Shineco公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗